GSA Capital Partners LLP Takes Position in Bristol Myers Squibb Company $BMY

GSA Capital Partners LLP acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 28,898 shares of the biopharmaceutical company’s stock, valued at approximately $1,665,000.

Several other institutional investors and hedge funds have also modified their holdings of BMY. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb in the 4th quarter worth about $25,000. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Physician Wealth Advisors Inc. grew its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Bayban bought a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Wall Street Analyst Weigh In

BMY has been the subject of several analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $63.86 on Monday. The stock’s 50-day simple moving average is $59.56 and its 200 day simple moving average is $59.00. The firm has a market capitalization of $130.45 billion, a PE ratio of 14.07, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.